{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-085432","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-08-05T13:27:18+00:00","discovered_at":"2026-08-05T13:28:03.126276+00:00","generated_at":"2026-08-05T13:28:08.587138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Oncology: new institutional accounts ordering LYMPHIR up 78% QoQ","bullets":["New institutions ordering LYMPHIR increased 78% in Q2 2026 vs. prior quarter; total vial orders up 31%.","LYMPHIR now available in 42 institutions including academic and NCCN centers.","Near-universal payer coverage achieved; initial CTCL market exceeds $400 million.","Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.","Wholesaler reorders have begun reflecting increased institutional demand; revenue recognized on filled wholesale orders."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-085432","json":"https://secwatch.observer/filing/0001213900-26-085432.json","markdown":"https://secwatch.observer/filing/0001213900-26-085432.md","text":"https://secwatch.observer/filing/0001213900-26-085432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/0001213900-26-085432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea0300373-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T13:28:08.587138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}